Henagliflozin's Impact on Prediabetes Remission
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 984 participants.
Also called NCT06448130
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 984 participants
- Sponsor
- Registry
-
NCT06448130
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06448130. Randomized; quadruple masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Henagliflozin's Impact on Prediabetes Remission
- Condition
- PreDiabetes
- Condition
- Prediabetic State
- Condition
- Type 2 Diabetes
- Condition
- Glucose Metabolism Disorders
- Intervention (Drug)
- Henagliflozin 5mg
- Intervention (Drug)
- Henagliflozin 10mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shandong Provincial Hospital
Record details
- Record id
cardio:ct-nct06448130- Content hash
29fb5ef895bf1ee7e5dac4648320ad784a18f88fe3a659291e4f1086039283ea